Pancreatitis - Microbiome as Predictor of Severity II

Launched by UNIVERSITY MEDICAL CENTER GOETTINGEN · Jul 17, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Pancreatitis - Microbiome as Predictor of Severity II," is studying how the bacteria and other tiny organisms in the gut may help predict how serious acute pancreatitis will be for patients. Acute pancreatitis is a condition where the pancreas becomes inflamed and can cause severe abdominal pain and other serious health issues. Researchers want to find out if analyzing the microbiome—basically the community of microbes living in our intestines—can give valuable information about the severity of the illness and how it might progress.

To be eligible for this study, participants need to be adults (18 years or older) who have just been diagnosed with acute pancreatitis within the last 48 hours and can provide consent. Unfortunately, those with a history of repeated pancreatitis episodes or signs of chronic pancreatitis will not be included. If you participate, you will provide samples like swabs from your mouth and rectum, as well as blood and stool, within two days of being admitted to the hospital. This research could help doctors better understand and manage acute pancreatitis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with initial diagnosis (\< 48h) of acute pancreatitis
• • Age ≥ 18 years
• • Patients able to understand/ give their written consent
• Exclusion Criteria:
• • Recurrent acute pancreatitis (\>2 previous episodes)
• • Clinical or imaging signs of chronic pancreatitis
• • Referred patients with length of hospital stay \> 48h